Related Experiment Video

Updated: May 13, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives

Dawn M Wahezi1, Norman T Ilowite

  • 1Children's Hospital at Montefiore, Division of Pediatric Rheumatology, Department of Pediatrics, 3415 Bainbridge Avenue, Bronx, NY 10467, USA. dwahezi@montefiore.org

Expert Opinion on Pharmacotherapy
|March 27, 2013
PubMed

Insights

Juvenile idiopathic arthritis (JIA) treatments have advanced, improving outcomes for children. Research consortia enhance understanding of biologic agent safety and efficacy in JIA management.

Area of Science:

  • Pediatric Rheumatology
  • Immunology

Background:

  • Juvenile idiopathic arthritis (JIA) is a prevalent childhood rheumatic disease.
  • Rapid therapeutic advances are leading to improved remission rates in JIA patients.

Purpose of the Study:

  • To review current JIA treatments for arthritis and systemic features.
  • To summarize evidence on the safety and efficacy of biologic agents in pediatric patients.
  • To discuss future therapeutic strategies for JIA management.

Main Methods:

  • Literature review of available JIA treatments.
  • Analysis of evidence supporting biologic agents' safety and efficacy.
  • Examination of future therapeutic approaches.

Main Results:

  • Pharmacotherapy advances have significantly improved physical and functional outcomes in JIA.
  • Research consortia facilitate large controlled studies, enhancing understanding of therapeutic agents.
  • Biologic agents show promise in managing JIA, with growing evidence of safety and efficacy.

Conclusions:

  • Significant improvements in JIA patient outcomes are attributed to pharmacotherapy advancements.
  • Collaborative research efforts have improved the understanding of JIA treatment safety and efficacy.
  • Long-term safety data for JIA therapies are limited, necessitating further extensive studies.
Abstract

More Related Videos

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...